I think you're right, we need to know if the Official Action from the EPO has accepted the complaint of ILNS. ( ... which we anticipate will be scheduled for early next year )
NEXT YEAR is now 2014
-------------------------------------------------
I wrote in my previous post: My intention was to report to the court Oing the conduct of Pfizer for trial Bapineuzumab ... This is to confirm what Shapiro said about conduct of Pfizer for trial Ponezumab ... --------------------------------------------- What do you think about? We must inform Shapiro about that?
-------------------------------------------------
Intellect Neurosciences Issues Letter to Shareholders
NEW YORK, Feb. 13, 2013 (GLOBE NEWSWIRE) ..........................
ANTISENILIN patents: For reasons that are unclear to us, Johnson & Johnson and Pfizer are continuing in their opposition to our ANTISENILIN patent in Europe, having responded quite aggressively to our appeal notice and submissions even after the Bapineuzumab Phase 3 results were announced. We are considering our response and strategy leading up to the Oral Hearings in Munich, which we anticipate will be scheduled for early next year. Meanwhile, we are waiting for an Official Action from the EPO with regard to our pending divisional patent application that aims to overcome the formalistic objections raised in the opposition. If the EOP grants us a patent on this second application, the opposition becomes moot. We received a first official action from the USPTO to our continuation-in-part application in which we are seeking additional claims, including to the amino terminus of Aß. We believe the arguments from the Examiner are quite straightforward to address and we are preparing our response. If successful, the issuance of this second patent would trigger another $2 million milestone payment from certain of our global pharmaceutical licensees.
News 
Market Data 
Discover 
